{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001777","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.947655+00:00","generated_at":"2026-06-27T05:33:58.877042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Biosciences reports Q4 net income of $279.4M on Gilead option exercise; cash ~$1.4B post-Gilead payments","bullets":["Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.","Net income Q4 $279.4M vs net loss $51.9M prior year; full-year net income $52.8M vs net loss $122.9M.","Cash, equivalents and investments $681.3M at Dec 31, 2021; plus $725M from Gilead in Jan 2022 = ~$1.4B, funding into 2026.","First patient dosed in PACIFIC-8 Phase 3 (domvanalimab + durvalumab in Stage 3 NSCLC); two more Phase 3 studies planned for 2022.","Data readouts for ARC-7 (domvanalimab/etrumadenant in NSCLC) and ARC-8 (quemliclustat in pancreatic cancer) expected 2H22."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001777","json":"https://secwatch.observer/filing/0000950170-22-001777.json","markdown":"https://secwatch.observer/filing/0000950170-22-001777.md","text":"https://secwatch.observer/filing/0000950170-22-001777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/0000950170-22-001777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/rcus-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:33:58.877042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}